1. Home
  2. CNEY vs HCWB Comparison

CNEY vs HCWB Comparison

Compare CNEY & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CN Energy Group Inc.

CNEY

CN Energy Group Inc.

HOLD

Current Price

$0.50

Market Cap

3.2M

Sector

Industrials

ML Signal

HOLD

Logo HCW Biologics Inc.

HCWB

HCW Biologics Inc.

BUY

Current Price

$1.48

Market Cap

3.6M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
CNEY
HCWB
Founded
2009
2018
Country
China
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2M
3.6M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
CNEY
HCWB
Price
$0.50
$1.48
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
310.8K
★ 748.9K
Earning Date
02-17-2027
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $4,099,750.00
Revenue This Year
N/A
$12,215.61
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$0.86
52 Week High
$2.63
$27.30

Technical Indicators

Market Signals
Indicator
CNEY
HCWB
Relative Strength Index (RSI) 37.33 31.82
Support Level $0.49 $0.86
Resistance Level $0.62 $3.07
Average True Range (ATR) 0.07 0.22
MACD -0.01 0.02
Stochastic Oscillator 19.35 1.21

Price Performance

Historical Comparison
CNEY
HCWB

About CNEY CN Energy Group Inc.

CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.

About HCWB HCW Biologics Inc.

HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.

Share on Social Networks: